Infliximab use in Crohn's disease: impact on health care resources in the UK.

OBJECTIVE: To quantify the impact of infliximab therapy on health care resource utilization in the UK. METHODS: A retrospective audit was undertaken at seven centres in the UK, which reviewed patient notes for a period of 6 months before and 6 months after an initial infliximab infusion. Details of...

Повний опис

Бібліографічні деталі
Автори: Jewell, D, Satsangi, J, Lobo, A, Probert, C, Forbes, A, Ghosh, S, Shaffer, J, Frenz, M, Drummond, H, Troy, G, Turner, S, Younge, L, Evans, L, Moosa, M, Rodgers-Gray, B, Buchan, S
Формат: Journal article
Мова:English
Опубліковано: 2005
_version_ 1826264415331155968
author Jewell, D
Satsangi, J
Lobo, A
Probert, C
Forbes, A
Ghosh, S
Shaffer, J
Frenz, M
Drummond, H
Troy, G
Turner, S
Younge, L
Evans, L
Moosa, M
Rodgers-Gray, B
Buchan, S
author_facet Jewell, D
Satsangi, J
Lobo, A
Probert, C
Forbes, A
Ghosh, S
Shaffer, J
Frenz, M
Drummond, H
Troy, G
Turner, S
Younge, L
Evans, L
Moosa, M
Rodgers-Gray, B
Buchan, S
author_sort Jewell, D
collection OXFORD
description OBJECTIVE: To quantify the impact of infliximab therapy on health care resource utilization in the UK. METHODS: A retrospective audit was undertaken at seven centres in the UK, which reviewed patient notes for a period of 6 months before and 6 months after an initial infliximab infusion. Details of hospital admissions, outpatient visits, operations, diagnostic procedures, drug usage, and overall efficacy were collected. Results were compared for the two 6 month study periods. RESULTS: A total of 205 patients (62% female, median age 33 years) with moderate/severe Crohn's disease were audited. The majority of patients had chronic active disease (62%) and most received one infusion initially (72%). Clinicians rated 74% of responses as good to excellent and patients 72%. Most patients had concomitant immunosuppression (pre: 75%, post: 75%). Approximately half of the patients (45%) stopped taking steroids, with a further 34% having a dosage reduction. A fall of 1093 inpatient days was seen (1435 vs. 342) in the 6 months following infliximab administration. There were seven fewer operations, 33 fewer examinations under anaesthetic, and 99 fewer diagnostic procedures. Outpatient visits were similar pre- versus post- (555 vs. 534). The total reduction in direct costs amounted to an estimated pounds 591,006. Three hundred and fifty-three infliximab infusions were administered at an estimated cost of pounds 562,719. Thus, there was a net reduction of pounds 28,287 or pounds 137.98 per patient. CONCLUSIONS: Infliximab appears to be a potentially cost effective treatment for selected patients based on the reduced number of inpatient stays, examinations under anaesthetic, and diagnostic procedures over a 6 month period.
first_indexed 2024-03-06T20:07:25Z
format Journal article
id oxford-uuid:295d7de6-863a-4edc-a2f5-368fca49dace
institution University of Oxford
language English
last_indexed 2024-03-06T20:07:25Z
publishDate 2005
record_format dspace
spelling oxford-uuid:295d7de6-863a-4edc-a2f5-368fca49dace2022-03-26T12:18:51ZInfliximab use in Crohn's disease: impact on health care resources in the UK.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:295d7de6-863a-4edc-a2f5-368fca49daceEnglishSymplectic Elements at Oxford2005Jewell, DSatsangi, JLobo, AProbert, CForbes, AGhosh, SShaffer, JFrenz, MDrummond, HTroy, GTurner, SYounge, LEvans, LMoosa, MRodgers-Gray, BBuchan, S OBJECTIVE: To quantify the impact of infliximab therapy on health care resource utilization in the UK. METHODS: A retrospective audit was undertaken at seven centres in the UK, which reviewed patient notes for a period of 6 months before and 6 months after an initial infliximab infusion. Details of hospital admissions, outpatient visits, operations, diagnostic procedures, drug usage, and overall efficacy were collected. Results were compared for the two 6 month study periods. RESULTS: A total of 205 patients (62% female, median age 33 years) with moderate/severe Crohn's disease were audited. The majority of patients had chronic active disease (62%) and most received one infusion initially (72%). Clinicians rated 74% of responses as good to excellent and patients 72%. Most patients had concomitant immunosuppression (pre: 75%, post: 75%). Approximately half of the patients (45%) stopped taking steroids, with a further 34% having a dosage reduction. A fall of 1093 inpatient days was seen (1435 vs. 342) in the 6 months following infliximab administration. There were seven fewer operations, 33 fewer examinations under anaesthetic, and 99 fewer diagnostic procedures. Outpatient visits were similar pre- versus post- (555 vs. 534). The total reduction in direct costs amounted to an estimated pounds 591,006. Three hundred and fifty-three infliximab infusions were administered at an estimated cost of pounds 562,719. Thus, there was a net reduction of pounds 28,287 or pounds 137.98 per patient. CONCLUSIONS: Infliximab appears to be a potentially cost effective treatment for selected patients based on the reduced number of inpatient stays, examinations under anaesthetic, and diagnostic procedures over a 6 month period.
spellingShingle Jewell, D
Satsangi, J
Lobo, A
Probert, C
Forbes, A
Ghosh, S
Shaffer, J
Frenz, M
Drummond, H
Troy, G
Turner, S
Younge, L
Evans, L
Moosa, M
Rodgers-Gray, B
Buchan, S
Infliximab use in Crohn's disease: impact on health care resources in the UK.
title Infliximab use in Crohn's disease: impact on health care resources in the UK.
title_full Infliximab use in Crohn's disease: impact on health care resources in the UK.
title_fullStr Infliximab use in Crohn's disease: impact on health care resources in the UK.
title_full_unstemmed Infliximab use in Crohn's disease: impact on health care resources in the UK.
title_short Infliximab use in Crohn's disease: impact on health care resources in the UK.
title_sort infliximab use in crohn s disease impact on health care resources in the uk
work_keys_str_mv AT jewelld infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT satsangij infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT loboa infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT probertc infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT forbesa infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT ghoshs infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT shafferj infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT frenzm infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT drummondh infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT troyg infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT turners infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT youngel infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT evansl infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT moosam infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT rodgersgrayb infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk
AT buchans infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk